AI & Predictive Modeling Are Transforming HEOR

For years, HEOR teams have focused on describing the past: analyzing retrospective claims, EMR data, and trial endpoints to understand treatment patterns and cost trajectories. But the next competitive edge in market access won’t come from explaining what happened. It...

CMS Transparency Rules: What Manufacturers Must Prepare For

The market access landscape is shifting. This time, the catalyst isn’t just pricing reform. It’s transparency. The Centers for Medicare & Medicaid Services (CMS) is expanding disclosure requirements around pricing, contracting, and value justification. What used...

Preparing for 2026: 5 Priorities for Market Access Leaders

2026 isn’t far off. Are your access priorities ready for the next wave of IRA-driven disruption? Between Inflation Reduction Act (IRA) implementation milestones, global pricing pressures, and payer adoption of new contracting models, the next 18 months will redefine...

From Insight to Action: Why Many Teams Stall at the Last Mile

Gathering insight is one thing. Acting on it fast enough to matter? That’s the real differentiator. Across pharma and biotech, manufacturers invest heavily in market access research—payer interviews, advisory panels, and data dashboards that reveal how coverage...

Linked EMR + Claims Data for Stronger HEOR Evidence

Manufacturers know that evidence is currency in payer negotiations. Fragmented datasets only tell a partial story that leaves payers skeptical. That’s why linked datasets have become the gold standard for health economics and outcomes research (HEOR). EMRClaims+ from...